Alphamab Oncology expects first annual profit in 2024

Alphamab Oncology (HKEX: 9966) announced it expects to report a profit of at least RMB 150 million for the year ended December 31, 2024, a substantial improvement compared to a loss of approximately RMB 210.6 million in the previous year. This positive shift, based on preliminary unaudited figures, is primarily attributed to revenue generated from three license collaborations and increased sales. The company advises shareholders and potential investors to exercise caution when dealing in the company shares as the annual results are still in the process of finalizing and may be subject to adjustments. The final results are expected to be published before the end of March 2025.